VIVE - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Viveve Third Quarter 2018 Financial Results Conference Call. [Operator Instructions].

Speaking today are Viveve's Chief Executive Officer and Director, Scott Durbin; and Jeannie Swindle, Senior Director of Corporate Communications.

Following an overview of the third quarter financial and operating results, the call will be opened up for questions. Please note, this event is being recorded. the to turn Swindle. now will call Jeannie over I

Jeannie Swindle

welcome, Thank and you, Operator, everyone.

are fully I prospects. as remind historical about events SEC, expectations, like conference company's we are a includes those of company. would on Before report begin, actual remarks risks is that which to These the that a call forward-looking financial website. of are and contain the analysis beliefs based the date not plans, and forward-looking in statements Any XX-K This from made statement of on future Form of more with on risks cause in call described forward-looking projections, you this are and the filings is subject conference regarding judgments the the and These future factual company's results statements corporation's or statement performance could available materially and uncertainties statements. important annual to differ the fact may also this that statement. other the to numerous and uncertainties described

In this addition, as should date. call conference over would statements our any be Durbin, only management's CEO. not conference representing upon now relied as and to of the date any management's turn the as views view of forward-looking subsequent like of I represent to Scott

Scott Durbin

any for from results. and platform. and quarter sold most everyone, sale made monopolar Viveve U.S. which the FDA's XX% X,XXX million was the I'd Communications pursuit far. of third of been treatment represents systems were XXXX number radiofrequency, or us And a urinary demonstrated like for some to XX affected address for of the $X.X -- joining July, quarterly $X.X third has record begin, and global this for million period sexual approvals globally, XX indications To a quarter for Good financial the notably profit of million which was in like for quarter our XXXX and Gross so the the tips, preeminent our on today. efforts or $X.X depth few pleased issue you financial and more tips Jeannie. sales compared of commercialization quarter rate was of same CMRF, success strong in the stress in highlight fronts U.S. cryogen-cooled, the market, of and late achieved market, XXXX. technology in that This in third to clinical growth Revenue thank -- disposable by the our a to Safety revenue. to advancements commercial function in incontinence XX% year-over-year am you, report morning, of issued third treatment minutes. of Thank I'd in significant quarter regulatory of results I revenue quarter for

through with was are direct our our and this our than partnership Partners. gross United relative our recently the and to expectations consoles for lower Aesthetic versus treatment and our proportion While distribution channels between the mix extremely the tips of in Management through sensitive sales product launched States quarter, internationally margins

X.X our we disposable impact margins negative margins because tips. of a gross this for a number gross our our the historically compared to tips, While as sold treatment on had Viveve period has record treatment system higher

system forward. tips margins we in in treatment going a and that began Viveve initial our in the will However, gross the we're pleased next-generation substantial our X.X QX, result which late launch of improvement to announce

respectively. cost XX% goods tips system a of In fact, our and new sold, in being through and reduction have large-scale manufactured now contract partners resulted treatment manufacturing in XX%

back half cost in we improvements Additionally, further gross margin efforts in XXXX. currently additional goods will that result of are the undergoing reduction sold of

the for over quarter driven expenses and On third XXXX increased the QX the The in for by XXXX was with total were and of quarter. expectations were sales increase our million $XX.X activities. side, primarily line operating expense marketing

As reducing and expenses will leverage various infrastructure. we to operational ways our move operating our continue evaluating focus forward, on we

many sheet a from ended now we third million Finally, our million competitors past by $XX.X $XX.X this Communication cash, expectations. marketing $XX.X comment as FDA's I'd received June with line in Safety decrease of from perspective, in with a million this the and we've XXXX, of take XX, balance the the a on to of seen summer. letters like to quarter few caused minutes by and impacts our was

letters and label efficacy plainfields a we a function of opportunities being move robust us the industry offered sexual receive X our and was set perspective in indications. patients, of paying gold our of believe ahead not to the you clinical towards technology, closer use And apart focused clinical in evidence us as be vaginal marketing competitors, intimate and the as not number from aware are is on more closer many attention in the creating safety safety and health who technology in the we to will consumer, in safety continue data the Viveve, of companies of the for letter. to benefited of X the by aware leveling we maybe our a of closer We outcomes physician indications. particular, believe SUI. profile devices preclinical and As Viveve approach, have and FDA the and and have standard that women's expansion clinical Because in unsurpassed CMRF clinical long-term leader reducing and

market. near-term headwinds there that the created no doubt However, is actions these FDA some in

caution for the cycle have, U.S. a lengthened others, a have systems new field seen as We the physician sales experienced result, to and, sales in like entering

annual costumers these few XX% and revenue to in the $XX.X our continue think Particularly $XX.X headwinds headwinds, will are these annual long-term, the actions recent in will end of revenue a to growth million, lowering in represents FDA XXXX quarters, we we to recent While that million doubt still guidance benefit XXXX. over face Viveve no which the XX% achieved volumes technology continue to have serve to to to treatment in continue tip and on our proud the clinical leader industry. our to customers physician a and the by and our in consumers we are this be recognized sales believe we the safety And firmly that as recorded resource as quarter we evidence. we profile as differentiation, educate

we towards in States As we made expansions in about Viveve rigorous SUI. LIBERATE-International the X urinary continues conducting: are tremendously for it's progress registration sexual seeking currently incontinence, II the commitment excited and function; for VIVEVE in label function we've sexual and stress United the trials are

to stress urinary incontinence. proud represent our for studies of trial most in expansion conduct represent Additionally, announced submission in have and, these multibillion-dollar IDE believe, industry the label improvement being LIBERATE-U.S. currently recently in the we're consumable our the for indications. we if Each opportunities markets, robust conducted successful, to studies, these to FDA future

to XXX trial preparing stage and a trial with effectiveness of patients. in safety to and assess multi-center, System August, rapid, the II, submit we data a function, This to the we've the randomized, X-month safety enrolled X- patients announced Enrollment are from patient month, in second staged XX sexual VIVEVE double-blind for Viveve IDE of of points. date an been enrollment. approval at improvement at sham-controlled follow-up and has least As received the

subjects endpoint Ministry primary clearances standardized proportion randomized includes rapidly, the of to more approval the in third the approximately waiting in safety, study in in efficacy, The quarter. in test active be in XXX greater Canada than XX to being worldwide, conducted as of recent international readout treatment urinary XXXX. other XX hope measured a FDA XXX successful, by FDA underway sites for this the and large IDE than also forward be to FDA and multiple proceeding of our multiple Canada, year-end multi-center, the to one a patients. in study international months. pursued experiencing sham-controlled through it's Subjects year-end, submitted and a randomized diary, of have X FDA the for stress X-hour this quality third year, international the in the LIBERATE-U.S. hope Health clearances X an we will the X-hour results and patients proposed outcome the scale the was registration LIBERATE-International, in reduction to sham-controlled from of scale and supplement second the weight on well continue study at September. randomized, hope primary design the X-day clearance Following affects including X/X the we trial to measured look total secondary in clinical this to also condition a is in treatments, IDE X:X is proposed support and intended at using and that a and full an IDE of for X as study, SUI safety treatments. are up subjects variety randomized, by will X be patients our ratio currently FDA double-blinded enrollment to and pad measures, efficacy to in up trial large to U.S. the trial date at by mark complete in submission if in in and active And and have efficacy initiated in of be the to from endpoints, is of And objective we that clearances. CMRF by of the study expected an begin estimated test. in study is sham approximately with the including to we weight XX% trial women ratio enrollment and and exploratory to the to pad sites. study Planned enrollment is the the trial understand in up submission. as as X:X voiding review X trial incontinence, double-blinded Enrollment Health the active studies, a enrollment life the of and a at use CE a expand are endpoint months quarter, the U.S., feedback for trial to with proposed next study approved mid-year Canadian sites XX XXX sham of the the U.S. registration and in technology being enrolled could at important patients LIBERATE-International, of The IDE

we addition may that being study, registration in Allan. to recall and currently results SUI our our June trials, in Bruce by X-month interim conducted from Dr. Canada In feasibility underway announced you

final approaching look XX-month forward clinical reporting to milestones SUI the next we the days. in final summary, XXXX; a for early and the over SUI quarter VIVEVE prepared LIBERATE-U.S. are the to of In and the days; expect and and readout look to this results Viveve, we IDE positive we in questions. is begin study approval next of study early year-end and SUI reiterate, within rapidly XX results the of extremely XX-month important like months. sexual remarks, end To final within feasibility or these Importantly, next II of was from finally, an results XX results Andrea? the by XX-month X-month series forward to to This XX the XXXX; mid-year to or at XXXX our XXXX. call we'd function the end announce in open LIBERATE-International

Operator

[Operator of Cowen Instructions]. our Jennings from question first and Josh comes And Co.

Joshua Jennings

decline wanted tailwinds just understand positive revision of, the the in what's to me? more guidance I excuse of hopefully you agreement with getting potentially then a competitors guess, that in Aesthetic fourth implied -- your also in Management some the bit have Partners, the with of to and have a terms here drivers U.S. -- the terms the partnership in Aesthetics dig in and play I that to letters just and be been quarter with just

Scott Durbin

has indications. of on market letters and getting the is of doubt and our we're based a that clinical and from near there long how term, physicians And remember their quarters. Again, safety although efforts. know a only of don't contracted, to was couple today going began the of inked sales too sure. the the that in we're Viveve. lengthened share the just they We in relationship FDA the to lost, we vaginal today Yes, placements. market United our at a predicting end AMP States of U.S. same the are experiencing being no have In evidence date, perspective larger believe, generated that's summer will new benefit sold the the for the long-term has perspective, that the cycle sort for profile benefited And while devices cautionary headwinds and they

Joshua Jennings

out just there consternation what customers? Is moving time you Or data forward? on the see anything to something Is in Great. in acute point further do could I And impact you of just confidence marketplace it from the more the where horizon? the could the we being, that foresee terms guess, away put be there to or clinical could that it quash catalyst there by physician you letters? this of is

Scott Durbin

a I fronts. Yes, think great question, you're it's and on both right

and those moving XX the the number at adoption into discerning and one, looking the now next we requires the of a and to of sold we expand evidence months more are the have hit prove the is the trial and the the catalysts laxity I for associated always long-term I sexual has will procedures safety XX think And XX and to in and their and in clinical continue opportunity. towards think market rapidly devices clinical our being to label practice you function of is these label, over this that procedures and United education. indications. our potential market time, of as those the types really significantly. label labels a continue And for expansion little we're countries Physicians to and with as increase device these respect it these more internationally. and ultimately evidence And States, into readouts know to pursue move our being vaginal view been to safe thankfully, start device bit amount over with that

Operator

comes question Jayson next Bedford James. Our of from Raymond

Jayson Bedford

did this you you that II, late XX-month few in a readout for to if end, mentioned at missed I Just the 'XX, VIVEVE the On expect VIVEVE II see early apologize I XXXX? questions.

Scott Durbin

presumes FDA. get second that And approval we that stage Yes. through the with

to and this most stage the which as mentioned was get As that enrollment, And to I to safety data fully that, data and clearance final and trial. a minimum X-month of certainly expectation, our from submitted second data safety mentioned I patients we defined remarks, in given FDA, data the imminently, our month. follow-up X-month with robustness prepared profile, the the will XX the of the be it's of the enroll submitting hope

incredibly has XXX-patient put we the already under So on enrollment are staged FDA us trial this in cap by rapidly, at and the gone enrollment.

know, a sexual baseline from once we the and opportunity VIVEVE the go think endpoint as II the to measuring study we up index. So have very will enrollment, open is continue it the quickly. XX-month And, female function change you in

Jayson Bedford

if on that's market current the the and understandable, in And has market helpful. sales contraction impacted cycle Okay, just is maybe at lengthened the then the this is understandable, all? price wondering

Scott Durbin

seen a We've impact on pricing not have market. it substantial in the

Jayson Bedford

Okay.

it the a letters, of Or seeing new utilization you from users? users? are of potential sales core terms In to of impact an your the is just impact in lengthening

Scott Durbin

the quarter the Yes, letters competitors. FDA evidenced Safety of FDA our and latter. any we've to that of QX statement of in number it's the over question. thus a letters FDA it the all midst by many great is tip performance had a And our Predominantly, in that's the of sales having far record treatment --

Jayson Bedford

Okay. then at appetite wondering in I'm one, if call last all? it impacted the here And U.S. noise to just the has internationally going

Scott Durbin

We've that. seen little a bit of

from So statements, of we only a been reflect FDA have been concern, a formal few countries, in but of wake and the other will, statement, the you other limited many. seen issue if sort it's countries. not the Safety same It's few

Operator

of Jon from next Our question Block comes Stifel.

Jonathan Block

with Scott, maybe margin. just the to start gross

there's quarters. some the handful really know big over You been past swings of

in XX% I environment. mentioned also and question front to big reductions have XX% to terms really to you of some in the Jason's stable think you of pricing alluded COG you You that range,

there is we tips systems to hard the i.e., can you approach? help phased-in where you the see immediately, real a both pricing of and on transfer cutover bit in -- GM And little just talk withheld? also more moves could a should natural big maybe or So there a us is offsets,

Scott Durbin

Yes.

scale higher are treatment legacy tips. our That historically, basis, this number than had system at right, our system our shifting launch two on very margins gross X.X. X.X of to gross Viveve margins has or with and Viveve dynamic sensitive on one, at the look, this So factors: very, is unusually

we'll prepared in of I robust more initially a As into we and rollout 'XX. have go mentioned the beginning at remarks, launched the X.X,

system to over gross be approach So phased the a improvement transition margin a will new that quarters. the course and of few

Importantly, biggest us take revenue a have it's market also system, United as clearly is time the to that the need our through the are we you well. perspective, world system understand selling go to while it the X.X and which that that on States, X.X will some process around we for from regulatory in

a sold period pointed sales of and well how by both has dependent lower So transfer mix our be margins. systems, international sales network, or through are of impact channel sales the also to and many you we it's in for either distribution factor obviously, and the our the of then proportionately And systems is, ASPs our tip U.S. And flowing obviously, then as a second and system AMP as in treatment contrast gross direct so pricing force selling has of unit as ASP. partnership quarters, recent distribution our the an out, and which, the will important couple that number on on volume

of the basis. quarter-by-quarter So us it's sensitivities two factors, predict on now to very difficult for from right because particularly a those

Jonathan Block

X Clearly, with that who in the out see or in are anything. got it. hard more. the there are you've Very selling and half to guidance, U.S., Okay, opinion, new the others back share, of my market 'XX gained Maybe not literally X helpful. but in be might

able you be may your to actually you North want you were when be market months dust to settles? this share maintain estimate, where American share boxes try level to on where the of think new when to expect ago? to relative do XX do guys So higher And you new

Scott Durbin

Yes, difficult I that's want to us. don't for because the latter estimate on very

assimilate data are market their these sort anecdotal that we longer in publicly the an know, sense based not quite gaining been have that of any of very are competitors, unit as share, many have there the people on and the of definitely given don't of large private or announced you products data We're marketing report and We indications for anecdotal basis, technology number the have companies but, them. makes selling we few confident on a and reduction volumes.

to So share. say it's tough

push willingness clinical clinical puts into there we market reading the -- the very forward, that know, path continue we dynamic expansion you as to believe towards significantly, forward. with a I because think practice our think to physicians' will of only be these company marketplace changes as the a in any And becoming that label, going these the are a the to and we just evidence ultimately safety but out company near procedures for as whole to have -- put indications. a adopt see position we the label us And trials of these leader term. will leading We we a the to not that. behind be in continuing profile that are their in also with that first

Jonathan Block

your one last point me, And trials. just for Okay. the to on

concluded. versus I trial a be And mitigated in trial might little different silly question, by former mentioned seem a LIBERATE-U.S. endpoint pretty and that maybe is a you of of is that, but expected proportion -- think Maybe is greater alluded big you other bit than I talk like recent to to? XX% a reduction. versus have that that that the placebo with can did that a your about What endpoint impact that patients Scott? to

Scott Durbin

question. important Yes, an

have overpowered, I LIBERATE-U.S. will We say,

a treated to the power perspective. the XXX rate the a group in -- exposed difference XX% a to it's with between we control the detect and are patients powering so And just of control have treated very of group high right? a powered from And reduction. for reduction, XX% patients, and we're a XX% anticipating group have

the follow-up. -- happen, will meaning a this trial the powered reduction. There's and this that time. they in is to we've fall off XX% arm with referencing, you that typical experience but And of others with placebo rate perspective, the XX% placebo a XX-month sham-control it trials, in nuance roughly, single may as treatment anticipating important not from significantly is literature a effects, over we're an versus be and XX%, powering generally So a in patients ours a to

test. the test a So as weight the is voiding a endpoint regard. in efficacy It's very it. this element weight also, And to endpoint, is benefit a XX-month us X-hour which to objective. is that subjective X-hour pad some has primary not pad diary

a we to a said, effect. being And anticipate placebo very low affect. so XX% powered placebo That we're

Operator

next question Yang Mizuho our comes And of Difei Securities. from

Difei Yang

Could one. next XX capital quick a in Just you needs the address the months?

Scott Durbin

this. remarks can't limited can comment, financing I Certainly. our about obviously, strategy. only make We on

the our infrastructure. As over to not but only prepared quarters, couple leverage that ways pay of in various evaluating I the expenses operational operating to continued to last mentioned significant them, remarks, we've attention reducing in

can't So those strategy. and comment or near-term of financing longer-term we to I are sort look things, me, continuing -- on excuse are we at

Difei Yang

Yes.

Just talk you about that, when a on do potentially to infrastructure, you product? selling mean the second leveraging follow-up

Scott Durbin

that be to anything current is to size, our constantly infrastructure, I to clearly that. and to certainly with experience sales the leverage don't that. want we're infrastructure, evaluating way and our I ways one want various clear about specific, so But do of scale reference operational

Operator

Our question of Anthony comes next from Maxim Group. Vendetti

Anthony Vendetti

treatment up margin just themselves, fluctuates Scott, the disposable The tips? gross I tips to lot, a for us the stage the on just general a margin. of the idea it range right? gross this follow give of treatment know at

Scott Durbin

are there tips. tips, comes of case reorder, Yes. with -- XX% on when is generally we every margin certain In tips instances, a have demo the to in free tips. which and gross the fact range, Anthony, for range I treatment account is a tree The that system

stages been to an And when sales, So -- obviously, when and down of market early from consumables, significantly margin in tips system where all versus it rate affected treatment the tips the it impact on is you perspective climbing report big placed. few ASP last treatment a that tips. start a quarters, that brings you ASP has although includes the development, the of has in substantially, reorder we for that placements over and phase the are gross

Anthony Vendetti

included are system many how tips because sale? a Understood in generally placement

Scott Durbin

least, case. at so Generally, six, X

Anthony Vendetti

which that XX Okay, have it literally sure true, expected days, even within expected the Do okay. is Is confident, of from any -- frame very you'll readout that the And December? I'm so of have of you Or feasibility is day? weeks from narrow study you more time readout? that seem SUI. the first couple

Scott Durbin

It is likely in early December.

Anthony Vendetti

December. Early

Okay. happens, a press should release? expect And when we that

Scott Durbin

Yes, weight endpoint particularly feasibility LIBERATE-U.S. we given SUI feasibility certainly from primarily the will XX-month the single be once using XX-month as potential the others it's recall study to the LIBERATE-International announce will pad it to of for that and study, SUI approved by is important success indicator the an us results, and FDA as well so in begin. here because treatment, as a X-hour duration

Operator

Thalmann Jeffrey next Co. comes Ladenburg from of Our Cohan question &

Jeffrey Cohen

So few, may. just a if I

what placements domestically that QX First, were the you've could the you talk about factor and form introduced? percent new

Scott Durbin

Sure.

QX we placed XX% system our roughly were globally, system. the in XX% of probably So about placements about X.X

Jeffrey Cohen

any commentary in may as how XXXX? and far Okay. they QX look And as

Scott Durbin

the probably much be maybe XXXX XX%. U.S. placements QX, on -- it In very of internationally little be it by driven a -- XX%, than system will heavier versus commentary yet. will but No number That's

Jeffrey Cohen

America? North And it. now us got organization of Okay, the remind size in the commercial

Scott Durbin

practice in includes reps sales we organization. the associate It XX as sales management A entire remains quarter. reps, capital the total team last it and same our leadership. of as well as reported recently Yes, people launched

Jeffrey Cohen

Okay.

XX AMP? So plus

Scott Durbin

Correct.

Jeffrey Cohen

for few addressable that you both bake the domestically then lastly, heard about Okay, thinking your as changed indications indications or this as we've there the the and as kind has market into on potentially, of got noise it. out the that? of And market, months, all the internationally think and as past size over far both

Scott Durbin

Absolutely, not.

we're is under to about physician contraction indication think technologies adopting I due general what without caution label. seeing a temporary a

opportunity preclin most the that and as this the think label, a is robust incontinence and I because efficacy function. in data market that, substantially. opportunity solution, single think ultimately that treatment stress clinical quite are lasts we market we immediately And sexual importantly, the the we in market, safety -- that months a enormous is have And urinary expands X XX battle noninvasive hopefully, as to the too, an we winning industry. evolve for

Operator

comes Northland Securities. Instructions]. Kalia our next [Operator of And question Suraj from

Suraj Kalia

maybe Given can can status call, on for -- any you shared the and it give everything color? on the is it idea already you you've sales you is but us this quo? shortening you happening side, cycle, Can give an all, us the of

Scott Durbin

Sure.

lower the remarks, length I the guidance think, and cycle wake several in the to I the publicity and mentioned actions the predominantly cause for came and letters cycle prepared the -- in the our year. it marketing of full received, competitors QX As sales that -- the of behind letter the to safety definitely is letter our sales has lengthened and

Suraj Kalia

of terms called competitive maybe it. me, been you you all with again, one Got forgive into been just the customers. can Have systems, up. these existing of customers and Scott, in And -- some

how new customers are from how are a getting they -- calls -- for handling are have trying existing your guys having to if placement, Cynosure or this? is example, for versus somebody paid and field customers? system say, placements -- on it, patients already what you Are going flow of it? who by blindsided understand are sort those of let's am I already all For has the is greenfield are Also into

Scott Durbin

It's thank a tough quantify. point great you. to a great that's question, Yes, and

Viveve to quarter. both relative profile of that date, the physician competitors' for -- increasing the physician one definitely the think, community one are our those of technologies. data definitely we dynamic that I from in are with historically the clinical me awareness, placements to And purchased playing we customers inbound out seeing our calls because of A today have in who receiving quantify safety inbound to calls. regarding little difficult and generated by the may

Suraj Kalia

of And application? data at LIBERATE, if am be but little see a us feel ask this is if is bit could reason to, for trying is remind I'll still And defined introduced I be there it. cheesy, just I Got Scott, there any protocol relative I least, variability? finally, ask, might a the that

Scott Durbin

there, before Yes, you go, it, were sorry, get please? repeat you didn't and up whole I question, breaking Suraj, could the you

Suraj Kalia

is guess, a am understand study? Well, variability what application I the for what be LIBERATE protocol or to there I saying any if introduced? I is could am defined trying is, offering in

Scott Durbin

important investigators it. our in a developed very announced thanks, that, well have trial. as conjunction you then a protocol training, the that with was LIBERATE-International we've bring process treatment Yes, got we study, our took new our SUI. we into and up robust for LIBERATE-U.S. precise an respect as our our go and on protocol feasibility and investigator of through defined with defined previously, and will both the procedure to trial we investigators component be advisers train to No, as for And that aspects trial very

Operator

Our question from of next comes Group. Craig-Hallum Capital Hewitt Matt

Matthew Hewitt

normally that given sure the presume, then information? change FDA's you coming scrutiny and change the gets putting watching you're on Just out? the they're it? as you that data, how that market how would might into out here some it simple have you the the environment as eyes with kind data up, that get how the going Does information does -- releases good of just market disseminate press First this Or physician of is the hoping want finding hands. FDA, to yet to kind term over some out over your near I make

Scott Durbin

forward change our I answer think question. is, a how it data intend that's present the trials. we Yes, great short present we through really doesn't move these as to or And

public for only but know, publication. you review, a data. society podium press of for forums as releases, presentation submitting meetings there peer well as journal of are Not presentations, As at lot the

pursue release continue to We will and data all think and forums, in to that's of intend our those don't changed. we

Matthew Hewitt

Well, that's Okay. great.

as Secondly, completed I'm any if very, get for sorry, but, strong buy one there last that obviously, from one, Was missed was of quarter or contribution a quarter? I this, very tips.

Scott Durbin

and system, as I program it our in, needed our as we related to change it out reported SUI. longer was X.X Viveve we the BOGO as our for no our tips, QX, to guess, design offer treatment system to as made Yes, both X.X for well software mid-August

program BOGO So X QX includes tips.

Matthew Hewitt

then and doctor kind the trying they to I really FDA, them just what the is, at one. been there on Or as now the educating versus was actual on them? physicians, really has strong very but Viveve this the -- one last best physicians steer any towards targeting I'm relying from guess, right for patients? treatment of Fantastic, And With cautiousness the well? a the performance. about patients educating get are obviously, maybe to is the

Scott Durbin

Thanks, Matt.

the physicians educating it predominantly think now. resides right I with

And marketing a know, no see As attained any fashion. in any a consumer nor in frankly, we has we going date, see of you these quite conduct on do we label indications. to don't -- one don't broad

education to effect So physician's date generated has expected to approvable us, that clinical of evidence for this. that and the to safety the today, single build and continue has educate physicians reliance treatment device. profile by continuing on with the around FDA recommendation installed a I move patient Viveve And the for as we set labels, the think, and durability it's about and it's towards it's particular really base our about

Operator

our Durbin question-and-answer closing concludes turn the for call remarks. his This to Scott back over session. I'll

Scott Durbin

you, Thank Thank We to questions. much who the you, call everyone, appreciate Thank analysts your the for this Andrea. morning. joined very you participation. again, our

towards continue was pioneering us, and will third result for of quarter importantly, achievements commercially the and, Together, a aggressively an trials, X our of of clearances to for regulatory of outstanding and in sexual leader a and from the function people. as the data focus tremendously health be as team the the women's United first will on you, States. both unparalleled believe ultimately, clinically registration towards be passionate intimate incontinence stress dedicated way what urinary our The and in improvement moving the we Thank by quarter everybody. readouts

Operator

attending has conference now concluded. Thank The for presentation. today's you

may disconnect. You now

Viveve Medical (VIVE) 9 Nov 182018 Q3 Earnings call transcript